DNA-PK-selective kinase inhibitor

oral efficacy in xenograft radiation models

undisclosed screening and optimization

Mol. Cancer Ther., Mar. 27, 2020

Merck KGaA, Darmstadt, DE

M3814

M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: